Cover Image
市場調查報告書

PharmaPoint:青光眼 - 全球醫藥品市場至2023年的預測與市場分析

PharmaPoint: Glaucoma - Global Drug Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 337336
出版日期 內容資訊 英文 333 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:青光眼 - 全球醫藥品市場至2023年的預測與市場分析 PharmaPoint: Glaucoma - Global Drug Forecast and Market Analysis to 2023
出版日期: 2015年05月11日 內容資訊: 英文 333 Pages
簡介

青光眼,是可預防的失明原因的全球第1名。現在可能的治療方法,是抑制青光眼的發病和進展的危險因子-眼壓 (IOP) 的上升。

本報告提供全球青光眼治療藥市場相關調查分析、疾病的概要與指南、競爭情形、主要藥物的詳細資訊 (產品說明、安全性、有效性) 、SWOT分析、銷售額預測、影響分析 (趨勢、推動因素、阻礙因素) 等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因、病理生理學
    • 病因
    • 病理生理學
  • 分類
  • 症狀
  • 預後

第4章 流行病學

  • 疾病的背景
  • 危險因素和共生病症
  • 全球趨勢
    • 美國
    • EU5個國家
    • 日本
  • 預測手法
    • 利用之資訊來源
    • 預測的前提條件與手法
    • 未利用之資訊來源
  • 流行病學預測
  • 討論

第5章 疾病的管理

  • 診斷和治療概要
  • 美國
  • EU5個國家
  • 日本

第6章 競爭評估

  • 概要
  • 產品簡介:領導品牌與藥效分類

第7章 未滿足需求和機會

第8章 開發平台評估

  • 概要
  • 臨床試驗
  • 臨床開發中的潛力藥物
  • 初期階段的有潛力的藥劑
  • 開發中的其他藥劑

第9章 現在、未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • Pfizer
    • Alcon
    • Allergan
    • 參天製藥
    • Aerie Pharmaceuticals
    • Inotek Pharmaceuticals
    • Bausch & Lomb
    • 興和
    • 大塚製藥

第10章 市場預測

  • 全球市場
  • 美國
  • EU5個國家
  • 日本

第11章 附錄

圖表

目錄
Product Code: GDHC112PIDR

Glaucoma is a leading cause of preventable blindness globally. This chronic progressive optic neuropathy causes irreversible vision loss through damage to the optic nerve. There are currently no treatments that can directly prevent this damage, and all commercially available glaucoma therapies focus on lowering elevated intraocular pressure (IOP), a known risk factor for glaucoma development and progression. The launch of fixed-dose combination (FDC) products, which combine drugs from these various classes, will continue to be a source of significant growth in this market. The glaucoma market is about to enter a phase of new growth with the arrival of first-in-class drugs, such as Aerie's Rhopressa, Bausch & Lomb's Vesneo (latanoprost bunod), and Inotek's trabodenoson into the 7MM during the forecast period, which will generate additional growth in the global glaucoma market.

Highlights

Key Questions Answered

  • The glaucoma market has been dominated by prostaglandin analogue (PGA) drugs in the last decade. New classes of drugs are anticipated the reach the market within the forecast period. How will these change the position the PGA drugs hold during the forecast period? Will these drugs maintain their market dominance in 2023?
  • The current late stage glaucoma pipeline is varied, with first-in-class drugs in development with innovative modes of action. Which of these will have the biggest impact on the market? What strategies are developers undertaking to penetrate this crowded and highly generic market? Will these fulfil any unmet needs?
  • Population aging is occurring in almost all countries worldwide, particularly in the 7MM. This is expected to have a significant impact on the prevalence of age-related diseases such as glaucoma. How will epidemiological changes impact the growth of the future market?

Key Findings

  • The main driver of growth in the glaucoma market will be the introduction of first-in-class drugs over the forecast period. The launch of three first-in-class therapies will grow this market. New fixed-dose drugs entering the 7MM will also act as a stimulant for growth.
  • The biggest barrier for growth in the glaucoma market will be the increasing use of generic latanoprost across the 7MM. The low cost of this therapy will increase the pressure on new drugs hoping to enter these markets to show drug cost-effectivness. This is likely to have a negative impact on these markets, as regulatory bodies are adopting stricter criterial for new drug approvals and reimbursement listing.
  • The largest unmet needs mainly reflect the notorious problem of poor patient adherence to therapy. Simplifying dosing regimens is an important consideration for companies developing drugs to treat these patients.

Scope

  • Overview of glaucoma, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized Glaucoma market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.
  • Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the glaucoma therapeutics market.
  • Pipeline analysis: focus on the eight late-stage pipeline glaucoma drugs discussing emerging trends as well as overview of earlier phase drugs.
  • Analysis of the current and future market competition in the global glaucoma therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global glaucoma therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global glaucoma therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global glaucoma therapeutics market from 2013-2023.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification
  • 3.3. Symptoms
  • 3.4. Diagnosis

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
    • 4.3.1. US
    • 4.3.2. 5EU
    • 4.3.3. Japan
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Forecast Assumptions and Methods
    • 4.4.3. Sources Not Used
  • 4.5. Epidemiological Forecast for Glaucoma (2013-2023)
    • 4.5.1. Total Prevalent Cases of Glaucoma
    • 4.5.2. Age-Specific Total Prevalent Cases of Glaucoma
    • 4.5.3. Sex-Specific Total Prevalent Cases of Glaucoma
    • 4.5.4. Age-Standardized Total Prevalence of Glaucoma
    • 4.5.5. Total Prevalent Cases of Glaucoma, by Clinical Type
    • 4.5.6. Total Prevalent Cases of NTG
    • 4.5.7. Diagnosed Prevalent Cases of POAG and PACG
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis and Treatment Overview
    • 5.1.1. Diagnosis
    • 5.1.2. Treatment Guidelines
    • 5.1.3. Leading Prescribed Drugs
    • 5.1.4. Clinical Practice
  • 5.2. US
  • 5.3. 5EU
  • 5.4. Japan

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Product Profiles - Main Brands and Drug Classes
    • 6.2.1. Xalatan (latanoprost)
    • 6.2.2. Lumigan (bimatoprost)
    • 6.2.3. Travatan (travoprost)
    • 6.2.4. Tapros (tafluprost)
    • 6.2.5. Beta Blockers
    • 6.2.6. Carbonic Anhydrase Inhibitors
    • 6.2.7. Alpha-Adrenergic Agonists
    • 6.2.8. Simbrinza (brinzolamide + brimonidine)
    • 6.2.9. Glanatec (ripasudil hydrochloride hydrate)

7. Unmet Need and Opportunity

  • 7.1. Overview
  • 7.2. Simplified Dosing Regimen
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. Reminder Systems
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. Long-Acting Therapy
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. New Classes of IOP-Lowering Drugs
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity
  • 7.6. Neuroprotective Drugs
    • 7.6.1. Unmet Need
    • 7.6.2. Gap Analysis
    • 7.6.3. Opportunity
  • 7.7. Improved Diagnosis and Monitoring
    • 7.7.1. Unmet Need
    • 7.7.2. Gap Analysis
    • 7.7.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Clinical Trials
    • 8.2.1. Clinical Trial Mapping
    • 8.2.2. Clinical Trial Design
  • 8.3. Promising Drugs in Clinical Development
    • 8.3.1. Rhopressa
    • 8.3.2. Roclatan
    • 8.3.3. Vesneo
    • 8.3.4. Bimatoprost SR
    • 8.3.5. Trabodenoson
    • 8.3.6. OPC-1085EL
    • 8.3.7. DE-117
    • 8.3.8. OXT-TP
  • 8.4. Promising Drugs in Early-Stage Development
    • 8.4.1. ROCK Inhibitor AMA-0076
    • 8.4.2. Sustained-Release PGA Products
  • 8.5. Other Drugs in Development

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Pfizer
    • 9.3.2. Alcon
    • 9.3.3. Allergan
    • 9.3.4. Santen
    • 9.3.5. Aerie Pharmaceuticals
    • 9.3.6. Inotek Pharmaceuticals
    • 9.3.7. Bausch & Lomb
    • 9.3.8. Kowa Company
    • 9.3.9. Otsuka Pharmaceutical

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. US
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. 5EU
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Japan
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Percent Drug-Treated Patients
    • 11.4.2. Drugs Included in Each Therapeutic Class
    • 11.4.3. Launch and Patent Expiry Dates
    • 11.4.4. General Pricing Assumptions
    • 11.4.5. Individual Drug Assumptions
    • 11.4.6. Pricing of Pipeline Agents
  • 11.5. Primary Research - KOLs Interviewed for this Report
  • 11.6. Primary Research - High-prescriber Survey
  • 11.7. About the Authors
    • 11.7.1. Analyst
    • 11.7.2. Therapy Area Director
    • 11.7.3. Epidemiologist
    • 11.7.4. Global Head of Healthcare
  • 11.8. About GlobalData
  • 11.9. Disclaimer

List of Tables

  • Table 1: Symptoms of Glaucoma
  • Table 2: Diagnostic Tests for Glaucoma.
  • Table 3: Types of Glaucoma
  • Table 4: Risk Factors and Comorbidities for Glaucoma
  • Table 5: 7MM, Sources of Glaucoma Total Prevalence Data Used in the Epidemiology Forecast
  • Table 6: 7MM, Sources of Epidemiological Data Used to Forecast the Total Prevalent Cases of Glaucoma Segmented by Clinical Types
  • Table 7: 7MM, Sources Not Used in the Epidemiological Analysis of Glaucoma
  • Table 8: 7MM, Total Prevalent Cases of Glaucoma, Ages ≥40 Years, Both Sexes, N, 2013-2023
  • Table 9: 7MM, Total Prevalent Cases of Glaucoma, by Age, Both Sexes, N (Row %), 2013
  • Table 10: 7MM, Total Prevalent Cases of Glaucoma, by Sex, Ages ≥40 Years, N (Row %), 2013
  • Table 11: 7MM, Total Prevalent Cases of Glaucoma, by Clinical Type, Ages ≥40 Years, N (Row %), 2013
  • Table 12: 7MM, Total Prevalent Cases of NTG, Ages ≥40 Years, Both Sexes, N, 2013-2023
  • Table 13: 7MM, Diagnosed Prevalent Cases of POAG, Ages ≥40 Years, Both Sexes, N, 2013-2023
  • Table 14: 7MM, Diagnosed Prevalent Cases of PACG, Ages ≥40 Years, Both Sexes, N, 2013-2023
  • Table 15: National and International Treatment Guidelines for Glaucoma
  • Table 16: Most Prescribed Drugs for Glaucoma in the Global Markets, 2013
  • Table 17: Country Profile - US
  • Table 18: Country Profile - 5EU
  • Table 19: Country Profile - Japan
  • Table 20: Leading Treatments for Glaucoma, 2013
  • Table 21: Product Profile - Xalatan
  • Table 22: Xalatan SWOT Analysis, 2014
  • Table 23: Global Sales Forecast ($m) for Xalatan, 2013-2023
  • Table 24: Global Sales Forecast ($m) for Generic Latanoprost, 2013-2023
  • Table 25: Product Profile - Lumigan
  • Table 26: Lumigan SWOT Analysis, 2014
  • Table 27: Global Sales Forecast ($m) for Lumigan, 2013-2023
  • Table 28: Product Profile - Travatan
  • Table 29: Travatan SWOT Analysis, 2014
  • Table 30: Global Sales Forecast ($m) for Travatan/Travatan Z, 2013-2023
  • Table 31: Global Overview of Tafluprost
  • Table 32: Product Profile - Tapros Franchise
  • Table 33: Tafluprost Adverse Events
  • Table 34: Tafluprost SWOT Analysis, 2014
  • Table 35: Global Sales Forecast ($m) for the Tapros Franchise, 2013-2023
  • Table 36: Beta Blockers Available in the 7MM
  • Table 37: Global Sales Forecast ($m) for Beta Blocker Drugs, 2013-2023
  • Table 38: Carbonic Anhydrase Inhibitors Available in the 7MM
  • Table 39: Global Sales Forecast ($m) for Carbonic Anhydrase Inhibitor Drugs, 2013-2023
  • Table 40: Alpha-Adrenergic Agonists available in the 7MM
  • Table 41: Global Sales Forecast ($m) for Alpha-Adrenergic Agonist Drugs, 2013-2023
  • Table 42: Product Profile - Simbrinza
  • Table 43: Simbrinza SWOT Analysis, 2014
  • Table 44: Global Sales Forecast ($m) for Simbrinza, 2013-2023
  • Table 45: Product Profile - Glanatec
  • Table 46: Glanatec SWOT Analysis, 2014
  • Table 47: Global Sales Forecast ($m) for Glanatec, 2013-2023
  • Table 48: Unmet Needs and Opportunities in Glaucoma
  • Table 49: Promising Drugs in Clinical Development for Glaucoma
  • Table 50: Comparison of Drugs in Development for Glaucoma, 2014
  • Table 51: Product Profile - Rhopressa
  • Table 52: SWOT Analysis - Rhopressa, 2014
  • Table 53: Global Sales Forecasts ($m) for Rhopressa, 2013-2023
  • Table 54: Product Profile - Roclatan
  • Table 55: SWOT Analysis - Roclatan, 2014
  • Table 56: Global Sales Forecasts ($m) for Roclatan, 2013-2023
  • Table 57: Product Profile - Vesneo
  • Table 58: SWOT Analysis - Vesneo, 2014
  • Table 59: Global Sales Forecasts ($m) for Vesneo, 2013-2023
  • Table 60: Product Profile - Bimatoprost SR
  • Table 61: SWOT Analysis - Bimatoprost SR, 2014
  • Table 62: Global Sales Forecasts ($m) for Bimatoprost SR, 2013-2023
  • Table 63: Product Profile - Trabodenosen
  • Table 64: SWOT Analysis - Trabodenoson, 2014
  • Table 65: Global Sales Forecasts ($m) for Trabodenosen, 2013-2023
  • Table 66: Product Profile - OPC-1085EL
  • Table 67: SWOT Analysis - OPC-1085EL, 2014
  • Table 68: Global Sales Forecasts ($m) for OPC-1085EL, 2013-2023
  • Table 69: Product Profile - DE-117
  • Table 70: SWOT Analysis - DE-117, 2014
  • Table 71: Product Profile - OXT-TP
  • Table 72: SWOT Analysis - OTX-TP, 2014
  • Table 73: Drugs in Development, 2014
  • Table 74: Key Companies in the Glaucoma Market in the 7MM, 2014
  • Table 75: Pfizer's Glaucoma Portfolio Assessment, 2014
  • Table 76: Alcon's Glaucoma Portfolio Assessment, 2014
  • Table 77: Allergan's Glaucoma Portfolio Assessment, 2014
  • Table 78: Santen's Glaucoma Portfolio Assessment, 2014
  • Table 79: Aerie's Glaucoma Portfolio Assessment, 2014
  • Table 80: Inotek's Glaucoma Portfolio Assessment, 2014
  • Table 81: Baush & Lomb/Valeant's Glaucoma Portfolio Assessment, 2014
  • Table 82: Kowa's Glaucoma Portfolio Assessment, 2014
  • Table 83: Otsuka's Glaucoma Portfolio Assessment, 2014
  • Table 84: Global Sales Forecast ($m) for Glaucoma, 2013-2023
  • Table 85: Glaucoma Market - Drivers and Barriers, 2013-2023
  • Table 86: US Sales Forecast ($m) for Glaucoma, 2013-2023
  • Table 87: Key Events Impacting Sales for Glaucoma in the US, 2013-2023
  • Table 88: Glaucoma Market - Drivers and Barriers in the US, 2013-2023
  • Table 89: 5EU Sales Forecast ($m) for Glaucoma, 2013-2023

Table 90 Key Events Impacting Sales for Glaucoma in the 5EU, 2013-2023 262

  • Table 91: Glaucoma Market - Drivers and Barriers in the 5EU, 2013-2023
  • Table 92: Japan Sales Forecast ($m) for Glaucoma, 2013-2023
  • Table 93: Key Events Impacting Sales for Glaucoma in Japan, 2013-2023
  • Table 94: Glaucoma Market - Drivers and Barriers in Japan, 2013-2023
  • Table 95: Key Launch Dates
  • Table 96: Key Patent Expiries
  • Table 97: Surveyed High-Prescribing Physicians (Non-KOLs), by Country

List of Figures

  • Figure 1: Open and Closed Iridocorneal Angles
  • Figure 2: The Aqueous Humor Cycle
  • Figure 3: Optic Nerve Damage - Cupping
  • Figure 4: Comparison of Healthy and Glaucomous Optic Nerves
  • Figure 5: 7MM, Total Prevalent Cases of Glaucoma, Ages ≥40 Years, Both Sexes, N, 2013-2023
  • Figure 6: 7MM, Total Prevalent Cases of Glaucoma, by Age, Both Sexes, N, 2013-2023
  • Figure 7: 7MM, Total Prevalent Cases of Glaucoma, by Sex, Ages ≥40 Years, N, 2013
  • Figure 8: 7MM, Age-Standardized Total Prevalence of Glaucoma, by Sex, Ages ≥40 Years, %, 2013
  • Figure 9: 7MM, Total Prevalent Cases of Glaucoma, by Clinical Type, Ages ≥40 Years, N, 2013
  • Figure 10: 7MM, Total Prevalent Cases of NTG, Ages ≥40 Years, Both Sexes, N, 2013-2023
  • Figure 11: 7MM, Diagnosed Prevalent Cases of POAG, Ages ≥40 Years, Both Sexes, N, 2013-2023
  • Figure 12: 7MM, Diagnosed Prevalent Cases of PACG, Ages ≥40 Years, Both Sexes, N, 2013-2023
  • Figure 13: Glaucoma Clinical Treatment Flowchart
  • Figure 14: Glaucoma - Number of Phase II and III/IIb Clinical Trials in Various Drug Classes in the 7MM
  • Figure 15: Competitive Assessment of Late-Stage Pipeline Agents in Glaucoma, 2013-2023
  • Figure 16: Rhopressa's Development in Glaucoma
  • Figure 17: Clinical and Commercial Positioning of Rhopressa
  • Figure 18: Roclatan's Development in Glaucoma
  • Figure 19: Clinical and Commercial Positioning of Roclatan
  • Figure 20: Vesneo Development in Glaucoma
  • Figure 21: Clinical and Commercial Positioning of Vesneo
  • Figure 22: Clinical and Commercial Positioning of Bimatoprost SR
  • Figure 23: Trabodenoson's Development in Glaucoma
  • Figure 24: Clinical and Commercial Positioning of Trabodenosen
  • Figure 25: OPC-1085EL's Development in Glaucoma
  • Figure 26: Clinical and Commercial Positioning of OPC-1085EL
  • Figure 27: DE-117's Development in Glaucoma
  • Figure 28: Global Sales of Branded Products for Glaucoma by Company, 2013-2023
  • Figure 29: Company Portfolio Gap Analysis in Glaucoma, 2013-2023
  • Figure 30: Global Sales for Glaucoma by Region, 2013-2023
  • Figure 31: Drug Sales by Class for Glaucoma, 2013 and 2023
  • Figure 32: Global Drug Sales by Class for Glaucoma, 2013-2023
  • Figure 33: Drug Sales by Class for Glaucoma in the US, 2013-2023
  • Figure 34: Drug Sales by Class for Glaucoma in the 5EU, 2013-2023
  • Figure 35: Drug Sales by Country for Glaucoma in the 5EU, 2013-2023
  • Figure 36: Drug Sales by Class for Glaucoma in Japan, 2013-2023
Back to Top